NCT06794853 Mechanism of TIPS to Improve Sarcopenia
| NCT ID | NCT06794853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Condition | Sarcopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 132 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 132 participants in total. It began in 2025-06-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sarcopenia is particularly common in patients with chronic liver disease, especially in patients with decompensated cirrhosis, where the prevalence can be more than 50%. Sarcopenia is an important risk factor for a significant increase in mortality in cirrhotic patients, and is closely associated with a high incidence of complications such as hepatic encephalopathy, ascites, and infections . Recent studies have found that TIPS not only significantly improves clinical symptoms caused by portal hypertension, but may also have a positive effect on skeletal muscle mass and function in patients. Although the effect of TIPS in improving sarcopenia has been preliminarily confirmed, its mechanism is not yet fully understood. Therefore, there is an urgent need to explore the mechanism of action of TIPS to improve sarcopenia and provide guidance for clinical treatment options.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with liver cirrhosis and needing TIPS surgical treatment; 2. Aged between 18-80 years old; 3. Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits. Exclusion Criteria: 1. Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.); 2. Suffering from malignant tumors and in the active stage; 3. Recent (within 3 months) history of major surgeries or traumas; 4. The presence of mental illness or cognitive disorders, which are unable to cooperate with the study; 5. Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06794853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06794853 currently recruiting?
Yes, NCT06794853 is actively recruiting participants. Contact the research team at 1946046224@qq.com for enrollment information.
Where is the NCT06794853 trial being conducted?
This trial is being conducted at Wuhan, Taiwan.
Who is sponsoring the NCT06794853 clinical trial?
NCT06794853 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 132 participants.